Chemcrux Enterprises Ltd

As of November 20, 2025, Chemcrux Enterprises is fairly valued with a PE ratio of 92.25, but has underperformed the Sensex with a year-to-date return of -32.58%, raising concerns about its growth prospects in the specialty chemicals sector.

As of 20-Nov, Chemcrux Enterprises Ltd's stock price is at 114.00, down 1.35 (-1.17%), reflecting a downward trend with a 4.84% decline over the last three days. The stock has significantly underperformed year-to-date and over the past year compared to the Sensex, indicating a bearish outlook.

As of November 7, 2025, Chemcrux Enterprises is overvalued with a PE ratio of 103.22 and low returns, underperforming the Sensex, making it a less attractive investment compared to its peers.

As of November 7, 2025, Chemcrux Enterprises is considered overvalued with a PE ratio of 103.22 and an EV to EBITDA of 16.95, significantly higher than its peers, and has experienced a year-to-date decline of 24.57%, contrasting with the Sensex's gain of 6.50%.

Chemcrux Enterprises' latest Q2 FY26 results are concerning, with net sales declining slightly and net profit dropping 81.74%, indicating significant operational challenges and declining profitability. The company's margins have contracted, and rising interest costs further exacerbate its financial difficulties.

Chemcrux Enterp. has shown a declining trend in financial performance over the past three years, with net sales and profits significantly decreasing while total assets and debt increased. The company has struggled with profitability and cash flow, resulting in a net cash outflow in the latest year.

As of 06-Nov, Chemcrux Enterprises Ltd's stock price is Rs 121.35, down 5.16% and has declined 14.48% over the last three days. The stock shows significant volatility and underperformance compared to the sector, with a year-to-date drop of 28.24% and a year-over-year decline of 39.22%.

As of November 4, 2025, Chemcrux Enterprises is fairly valued with a PE ratio of 68.40, facing challenges with a year-to-date return of -24.33%, and lower profitability metrics compared to peers, indicating the need for close monitoring of its operational efficiency and market conditions.

As of November 4, 2025, Chemcrux Enterprises is fairly valued with a PE Ratio of 68.40, an EV to EBITDA of 24.01, and a Price to Book Value of 2.54, despite a year-to-date decline of 24.33% and a PEG Ratio of 0.00 indicating no growth expectations.

As of 04-Nov, Chemcrux Enterprises Ltd's stock price is 127.95, down 6.81%, reflecting significant volatility and a year-to-date decline of 24.33%. The stock has underperformed compared to the benchmark Sensex, indicating unfavorable market sentiment.

As of October 31, 2025, Chemcrux Enterprises is considered overvalued with a PE ratio of 74.31 and poor stock performance, significantly higher than its peers, indicating a lack of justification for its premium pricing.

As of October 31, 2025, Chemcrux Enterprises is considered overvalued with a PE ratio of 74.31 and poor stock performance, especially compared to peers like Godrej Industries and Gujarat Fluoroch.

As of October 31, 2025, Chemcrux Enterprises is overvalued with a high PE ratio of 74.31 and poor performance metrics, including a year-to-date decline of 17.8%, indicating a shift from fair to expensive valuation.

As of 31-Oct, Chemcrux Enterprises Ltd is experiencing a price increase to Rs 139.00, reflecting a rise of 5.14%. The stock has shown strong short-term performance, significantly outperforming the Sensex and indicating a recovery trend despite year-to-date challenges.

Chemcrux Enterp. has experienced a significant decline in financial performance over the past three years, with net sales dropping from 95.15 Cr to 70.01 Cr, and profits before and after tax decreasing substantially. Additionally, total liabilities increased, while cash flow from operating activities fell, resulting in a net cash outflow of -4.00 Cr in Mar'25.

As of 30-Oct, Chemcrux Enterprises Ltd's stock price has risen to Rs 132.20, up 19.53%, with strong performance and increased investor participation. Despite a year-to-date decline, recent gains indicate a potential recovery phase for the stock.

Chemcrux Enterp. has experienced a consistent decline in net sales and profits over the past three years, with net sales dropping from 95.15 Cr in March 2023 to 70.01 Cr in March 2025, while total liabilities increased significantly. The company faces a challenging financial environment, marked by decreasing cash flow and rising expenditures.